These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 7863853)

  • 1. Pharmacokinetics of melarsoprol in uninfected vervet monkeys.
    Burri C; Onyango JD; Auma JE; Burudi EM; Brun R
    Acta Trop; 1994 Oct; 58(1):35-49. PubMed ID: 7863853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic properties of the trypanocidal drug melarsoprol.
    Burri C; Baltz T; Giroud C; Doua F; Welker HA; Brun R
    Chemotherapy; 1993; 39(4):225-34. PubMed ID: 8391966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigations of the metabolites of the trypanocidal drug melarsoprol.
    Keiser J; Ericsson O; Burri C
    Clin Pharmacol Ther; 2000 May; 67(5):478-88. PubMed ID: 10824626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trypanosoma brucei rhodesiense: use of an antigen detection enzyme immunoassay for evaluation of response to chemotherapy in infected vervet monkeys (Cercopithecus aethiops).
    Gichuki CW; Nantulya VM; Sayer PD
    Trop Med Parasitol; 1994 Sep; 45(3):237-42. PubMed ID: 7899795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An in vitro bioassay for quantification of melarsoprol in serum and cerebrospinal fluid.
    Burri C; Brun R
    Trop Med Parasitol; 1992 Dec; 43(4):223-5. PubMed ID: 1293724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic investigations in patients from northern Angola refractory to melarsoprol treatment.
    Burri C; Keiser J
    Trop Med Int Health; 2001 May; 6(5):412-20. PubMed ID: 11348536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of trypanocidal therapy on the haematology of vervet monkeys experimentally infected with Trypanosoma brucei rhodesiense.
    Ngotho M; Kagira JM; Kariuki C; Maina N; Thuita JK; Mwangangi DM; Farah IO; Hau J
    Acta Trop; 2011 Jul; 119(1):14-8. PubMed ID: 21420376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An automated biological assay to determine levels of the trypanocidal drug melarsoprol in biological fluids.
    Onyango JD; Burri C; Brun R
    Acta Trop; 2000 Jan; 74(1):95-100. PubMed ID: 10643913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative application of melarsoprol for treatment of T. B. gambiense sleeping sickness. Preliminary results.
    Burri C; Blum J; Brun R
    Ann Soc Belg Med Trop; 1995 Mar; 75(1):65-71. PubMed ID: 7794064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial.
    Burri C; Nkunku S; Merolle A; Smith T; Blum J; Brun R
    Lancet; 2000 Apr; 355(9213):1419-25. PubMed ID: 10791526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis.
    Nok AJ
    Parasitol Res; 2003 May; 90(1):71-9. PubMed ID: 12743807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ELISA assay for melarsoprol.
    Maes L; Doua F; Hamers R
    Bull Soc Pathol Exot Filiales; 1988; 81(3 Pt 2):557-60. PubMed ID: 3197252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma brucei gambiense sleeping sickness.
    Pépin J; Milord F; Khonde AN; Niyonsenga T; Loko L; Mpia B; De Wals P
    Trans R Soc Trop Med Hyg; 1995; 89(1):92-7. PubMed ID: 7747321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gambiense trypanosomiasis: frequency of, and risk factors for, failure of melarsoprol therapy.
    Pépin J; Milord F; Khonde A; Niyonsenga T; Loko L; Mpia B
    Trans R Soc Trop Med Hyg; 1994; 88(4):447-52. PubMed ID: 7570842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemia.
    Soignet SL; Tong WP; Hirschfeld S; Warrell RP
    Cancer Chemother Pharmacol; 1999; 44(5):417-21. PubMed ID: 10501916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The monitoring of trypanocidal treatment with a sensitive ELISA method for measuring melarsoprol levels in serum and in cerebrospinal fluids.
    Maes L; Vanderveken M; Hamers R; Doua F; Cattand P
    Ann Soc Belg Med Trop; 1988 Sep; 68(3):219-31. PubMed ID: 3223784
    [No Abstract]   [Full Text] [Related]  

  • 17. Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness.
    Bisser S; N'Siesi FX; Lejon V; Preux PM; Van Nieuwenhove S; Miaka Mia Bilenge C; Būscher P
    J Infect Dis; 2007 Feb; 195(3):322-9. PubMed ID: 17205469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of the trypanocidal drug melarsoprol and its conversion products in biological fluids with HPLC-ICPMS/ESMS.
    Raber G; Raber T; Raml R; Murko M; Magnes C; Francesconi KA
    Talanta; 2013 Nov; 116():876-81. PubMed ID: 24148488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eflornithine concentrations in serum and cerebrospinal fluid of 63 patients treated for Trypanosoma brucei gambiense sleeping sickness.
    Milord F; Loko L; Ethier L; Mpia B; Pépin J
    Trans R Soc Trop Med Hyg; 1993; 87(4):473-7. PubMed ID: 8249087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. African trypanosomiasis and drug-induced encephalopathy: risk factors and pathogenesis.
    Pepin J; Milord F
    Trans R Soc Trop Med Hyg; 1991; 85(2):222-4. PubMed ID: 1887477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.